Google
CELU — CELULARITY INC (Healthcare >> Biotechnology)
CELU FAQ
What is CELU's ROE?
CELULARITY INC reports a Return on Equity (ROE) of 253.06%.
What is CELU's dividend yield?
CELULARITY INC offers a dividend yield of 0.00%.
What is CELU's Deepscope Quality Score?
Deepscope rates CELU's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy CELU?
Deepscope's AI Timing Score for CELU is 50 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does CELU belong to?
CELULARITY INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 1.02
Price
-0.04
(-3.77%)
Day Change
|
|
|---|
CELU, ファンダメンタルスコアはnot good ( ファンダメンタル = 23) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 1.02 |
| PBV / Sector |
-0.81 / 4.48
|
| Earning Per Share | -3.20 |
| PE / Sector |
N/A / 16.68
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
0.13 M
GREAT
|
| Average 1W Daily Value |
0.16 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
39% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-04 09:24:24 |
| Symbol | CELU |
| Name | CELULARITY INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 28.95 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 30.68 / 8,483.11 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 170 Park Avenue, Florham Park, NJ, United States, 07932
Phone: 908 768 2170
Website: https://www.celularity.com
Employees: 115
Sector: Healthcare >> Biotechnology
Description: Celularity Inc., a cellular and regenerative medicine company, focuses on addressing aging-related disease using novel therapies. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating multiple sclerosis, rheumatoid arthritis, stroke, and diabetic peripheral neuropathy. The company also produces, sells, and licenses products used in surgical and wound care markets, such as Biovance, Biovance 3L, Rebound, Interfyl, and Centaflex; and collects, processes, and stores umbilical cord and placental blood and tissue after full-term pregnancies under the LifebankUSA brand. Celularity Inc. has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. Celularity Inc. was founded in 1998 and is headquartered in Florham Park, New Jersey.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
